Summary：Nephros to Share Breakthrough Insights at Health, Wellness & Longevity Summit **Introduction** Nep

Nephros to Share Breakthrough Insights at Health, Wellness & Longevity Summit

**Introduction**
Nephros, Inc., a leader in water purification and infection‑prevention technologies, announced today that it will present groundbreaking findings at the upcoming Health, Wellness & Longevity Summit in San Diego. The company’s presentation, scheduled for the summit’s second day, will focus on novel data linking advanced filtration systems to improved patient outcomes in chronic kidney disease (CKD) management. Industry observers anticipate that the insights could reshape how healthcare providers approach renal care and preventive wellness strategies.

**Key Developments**
At the summit, Nephros will unveil results from a multi‑center clinical trial evaluating its proprietary Dual‑Stage Filtration (DSF) technology in hemodialysis patients. Preliminary data indicate a 22 % reduction in inflammatory markers and a 15 % improvement in ultrafiltration efficiency compared with standard care. Additionally, the firm will showcase a new point‑of‑use water safety module designed for outpatient clinics, which demonstrated a 99.9 % removal rate of bacterial endotoxins in laboratory testing. These advancements underscore Nephros’ commitment to integrating infection control with therapeutic efficacy.

**Industry Analysis**
The renal care sector is experiencing a paradigm shift toward preventive, technology‑driven models. According to a recent market report, global spending on dialysis-related infection prevention is projected to exceed $4.3 billion by 2028, driven by rising CKD prevalence and stricter regulatory standards. Nephros’ DSF platform addresses two critical pain points: microbial contamination and fluid management inefficiencies. Analysts note that companies offering combined filtration and therapeutic benefits are likely to capture a larger share of hospital budgets, especially as value‑based care incentives prioritize reduced complication rates. The summit’s audience—comprising clinicians, policymakers, and investors—will thus be well positioned to assess the commercial and clinical implications of Nephros’ latest data.

**Future Outlook**
Looking ahead, Nephros plans to pursue FDA clearance for an expanded indication of its DSF system to include peritoneal dialysis settings. The company also intends to partner with integrated health networks to pilot real‑world outcome studies that track hospitalization rates and quality‑of‑life metrics over 12 months. If these initiatives succeed, Nephros could set